Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 11Sarcoma 6Neoplasms 6Lymphoma, Mantle-Cell 6Prostatic Neoplasms 5Lymphoma, Non-Hodgkin 5Rhabdomyosarcoma 4Neoplasm Metastasis 4Kidney Neoplasms 4Gliosarcoma 4Glioblastoma 4Breast Neoplasms 4Brain Neoplasms 4Waldenstrom Macroglobulinemia 3Osteosarcoma 3Melanoma 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Endometrial Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Liposarcoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Hepatocellular 2

Interventions

Gemcitabine 14Cisplatin 13Capecitabine 11Paclitaxel 9Oxaliplatin 9Fluorouracil 9130-nm albumin-bound paclitaxel 9pembrolizumab 7Albumin-Bound Paclitaxel 7Ramucirumab 6Leucovorin 6Carboplatin 6Bevacizumab 6Nivolumab 5Irinotecan 5Docetaxel 5Pemetrexed 4Everolimus 4Erlotinib Hydrochloride 4Cyclophosphamide 4trastuzumab deruxtecan 3Radiotherapy 3Afatinib 3zolbetuximab 2trifluridine tipiracil drug combination 2regorafenib 2pralsetinib 2cabozantinib 2Trastuzumab 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma × temsirolimus × Clear all
NCT00106353 2013-02-08

Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

Pfizer

Phase 1/2 Completed
71 enrolled 42 charts
Tumor-Agnostic

Adenocarcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡